摘要
目的:探讨清肺解毒化痰方(Qingfei-Jiedu-Huatan formula,QJHF)对肺炎克雷伯杆菌诱导的重症肺炎小鼠肺血管内皮屏障损伤的作用及其机制。方法:将51只C57BL/6J小鼠随机分为对照组(n=6)、模型组(n=15)、QJHF组(n=15)和头孢曲松钠(ceftriaxone sodium,CRO)组(n=15)。第0天一次性气管插管注入50μL浓度为1×10^(11)CFU/mL肺炎克雷伯杆菌制备重症肺炎小鼠模型。造模6 h后,QJHF组和CRO组分别给予相应药物治疗,其余组给予等体积生理盐水,第3天灌胃结束后处死小鼠。苏木素-伊红染色法观察肺组织病理改变;ELISA检测肺组织匀浆中肿瘤坏死因子α(tumor necrosis factor-α,TNF-α)、白细胞介素1β(interleukin-1β,IL-1β)和IL-6水平;流式细胞术检测支气管肺泡灌洗液(bronchoalveolar lavage fluid,BALF)中CD11b+Ly6g+细胞数;蛋白质组学及网络药理学分析药物作用机制;Western blot检测肺组织血管内皮钙黏蛋白(vascular endothelial cadherin,VE-cadherin)、闭锁小带蛋白1(zonula occludens-1,ZO-1)、闭合蛋白(occludin)、血管内皮生长因子(vascular endothelial growth factor,VEGF)、P38丝裂原活化蛋白激酶和磷酸化P38(phosphorylated P38,p-P38)蛋白水平。结果:QJHF可显著改善重症肺炎模型小鼠的精神状态,缓解呼吸促动等症状,降低死亡率,减轻肺组织病变,降低肺组织IL-6、TNF-α和IL-1β水平,减少BALF总蛋白、总细胞数和中性粒细胞含量,增加肺组织VE-cadherin、ZO-1和occludin蛋白表达(P<0.05或P<0.01)。蛋白质组学显示QJHF可逆转重症肺炎小鼠肺组织中129个蛋白的表达;网络药理学显示QJHF的14种主要入血成分的328个潜在靶点与1665个重症肺炎疾病基因共有125个交集基因。将逆转蛋白与交集基因构建蛋白质相互作用网络,GO富集分析和KEGG通路富集分析显示,QJHF主要调控PI3K-Akt、MAPK和Rap1信号通路及VEGFR等。Western blot结果显示,QJHF可显著抑制肺组织中VEGF和P38表达(P<0.05或P<0.01)。结论:QJHF减轻重症肺炎模型小鼠肺病理损伤,机制可能与抑制VEGF/P38信号通路、保护小鼠血管内皮屏障有关。
AIM:To investigate the effects of the Qingfei-Jiedu-Huatan formula(QJHF)on damage to the lung vascular endothelial barrier induced by Klebsiella pneumoniae in mice with severe pneumonia,as well as to elucidate its underlying mechanisms.METHODS:Fifty-one C57BL/6J mice were randomly divided into control group(n=6),model group(n=15),QJHF group(n=15),and ceftriaxone sodium(CRO)group(n=15).Severe pneumonia was in-duced in the mice by a single tracheal intubation with 50μL of 1×10^(11)CFU/mL Klebsiella pneumoniae on day 0.Six hours after modeling,the mice in QJHF and CRO groups received their respective treatments,while those in control and model groups were administered an equal volume of saline.All mice were sacrificed on day 3 after the end of gavage.Lung histo-pathological changes were assessed using hematoxylin-eosin(HE)staining.Levels of tumor necrosis factor-α(TNF-α),interleukin-1β(IL-1β),and IL-6 in lung tissues were measured by enzyme-linked immunosorbent assay(ELISA).Flow cytometry was used to detect CD11b+Ly6g+cells in bronchoalveolar lavage fluid(BALF).Proteomics and network pharma-cology analyses were conducted to elucidate the mechanisms of drug action.Western blot was conducted to assess the ex-pression levels of vascular endothelial cadherin(VE-cadherin),zonula occludens-1(ZO-1),occludin,vascular endothe-lial growth factor(VEGF),P38 mitogen-activated protein kinase(P38),and phosphorylated P38(p-P38)in lung tis-sues.RESULTS:Treatment with QJHF significantly attenuated the symptoms such as mental status and respiratory dis-tress,reduced mortality,mitigated lung tissue lesions,and decreased levels of IL-6,TNF-α,IL-1β,as well as BALF to-tal protein concentration,total cell count and neutrophil content in a mouse model of severe pneumonia(P<0.05 or P<0.01).Additionally,QJHF increased the expression of VE-cadherin,ZO-1 and occludin proteins in lung tissues.Pro-teomic analysis demonstrated that QJHF modulated the expression of 129 proteins in the lung tissues of mice suffering from severe pneumonia.Network pharmacology identified 328 potential targets associated with 14 major bioactive components of QJHF and 1665 genes related to severe pneumonia,with 125 overlapping genes between the two datasets.The construc-tion of a protein-protein interaction(PPI)network,along with Gene Ontology(GO)and Kyoto Encyclopedia of Genes and Genomes(KEGG)enrichment analyses of the regulated proteins and overlapping genes,indicated that QJHF primarily in-fluenced the PI3K-Akt,MAPK and Rap1 signaling pathways,as well as VEGFR.Western blot analysis showed that QJHF significantly inhibited the expression of VEGF and P38 in lung tissues(P<0.05 or P<0.01).CONCLUSION:Treatment with QJHF attenuates severe pneumonia in mice,potentially by inhibiting VEGF/P38 signaling to protect the vascular endothelial barrier.
作者
程思远
白云苹
程俞梦
万冉
邢小香
赵鹏
李建生
CHENG Siyuan;BAI Yunping;CHENG Yumeng;WAN Ran;XING Xiaoxiang;ZHAO Peng;LI Jiansheng(Collaborative Innovation Center for Chinese Medicine and Respiratory Diseases Co-constructed by Henan Province&Ministry of Education,Henan Key Laboratory of Chinese Medicine for Respiratory Disease,Henan University of Chinese Medicine,Zhengzhou 450046,China;Academy of Chinese Medical Sciences,Henan University of Chinese Medicine,Zhengzhou 450046,China;The First Affiliated Hospital of Henan University of Chinese Medicine,Zhengzhou 450000,China)
出处
《中国病理生理杂志》
北大核心
2025年第3期524-533,共10页
Chinese Journal of Pathophysiology
基金
国家自然科学基金资助项目(No.81904170)
河南省“双一流”创建学科中医学科学研究专项(No.HSRP-DFCTCM-2023-1-06)
呼吸疾病中医药防治科技创新团队资助项目(No.HSRP-DFCTCM-T-1)
2024年度河南省高校科技创新人才支持计划资助项目(No.24HASTIT073)。
